Canaccord Genuity Group Forecasts Strong Price Appreciation for LifeStance Health Group (NASDAQ:LFST) Stock

LifeStance Health Group (NASDAQ:LFST) had its price target raised by stock analysts at Canaccord Genuity Group from $9.00 to $10.00 in a research note issued to investors on Thursday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Canaccord Genuity Group’s price target would indicate a potential upside of 38.12% from the company’s previous close.

Several other analysts have also recently commented on LFST. Zacks Research cut LifeStance Health Group from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, November 5th. BMO Capital Markets assumed coverage on LifeStance Health Group in a research note on Thursday, November 13th. They issued an “outperform” rating and a $8.00 price objective for the company. Wall Street Zen raised LifeStance Health Group from a “hold” rating to a “buy” rating in a research note on Sunday, February 8th. Barclays started coverage on LifeStance Health Group in a report on Tuesday, December 9th. They issued an “overweight” rating and a $8.00 target price on the stock. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of LifeStance Health Group in a research report on Monday, December 29th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $9.67.

LifeStance Health Group Stock Performance

Shares of LFST opened at $7.24 on Thursday. The company has a 50-day moving average of $7.13 and a two-hundred day moving average of $6.20. The stock has a market cap of $2.82 billion, a price-to-earnings ratio of 362.18 and a beta of 1.12. The company has a debt-to-equity ratio of 0.18, a current ratio of 1.58 and a quick ratio of 1.58. LifeStance Health Group has a one year low of $3.74 and a one year high of $8.30.

LifeStance Health Group (NASDAQ:LFST) last issued its quarterly earnings results on Wednesday, February 25th. The company reported $0.03 EPS for the quarter, missing the consensus estimate of $0.05 by ($0.02). LifeStance Health Group had a net margin of 0.68% and a return on equity of 0.66%. The firm had revenue of $382.20 million during the quarter, compared to analysts’ expectations of $378.51 million. During the same quarter last year, the company posted ($0.01) EPS. The firm’s revenue was up 17.4% compared to the same quarter last year. On average, equities research analysts expect that LifeStance Health Group will post -0.18 earnings per share for the current year.

LifeStance Health Group announced that its board has authorized a share buyback program on Wednesday, February 25th that permits the company to buyback $100.00 million in shares. This buyback authorization permits the company to repurchase up to 3.6% of its shares through open market purchases. Shares buyback programs are generally a sign that the company’s board of directors believes its shares are undervalued.

Insider Activity

In other LifeStance Health Group news, Director Robert Bessler sold 119,942 shares of LifeStance Health Group stock in a transaction that occurred on Friday, December 19th. The shares were sold at an average price of $7.04, for a total value of $844,391.68. Following the completion of the sale, the director directly owned 1,318,983 shares in the company, valued at $9,285,640.32. The trade was a 8.34% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Ann Varanakis sold 50,000 shares of the stock in a transaction on Wednesday, December 17th. The stock was sold at an average price of $6.90, for a total transaction of $345,000.00. Following the transaction, the insider owned 315,610 shares in the company, valued at approximately $2,177,709. This trade represents a 13.68% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 270,086 shares of company stock valued at $1,891,264. 3.20% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On LifeStance Health Group

Several institutional investors and hedge funds have recently modified their holdings of the business. Park Edge Advisors LLC increased its position in LifeStance Health Group by 14.4% during the fourth quarter. Park Edge Advisors LLC now owns 11,863 shares of the company’s stock worth $84,000 after buying an additional 1,495 shares during the last quarter. California State Teachers Retirement System boosted its stake in shares of LifeStance Health Group by 1.6% during the 4th quarter. California State Teachers Retirement System now owns 125,682 shares of the company’s stock worth $885,000 after acquiring an additional 1,966 shares in the last quarter. Vident Advisory LLC increased its holdings in shares of LifeStance Health Group by 12.7% during the 2nd quarter. Vident Advisory LLC now owns 21,732 shares of the company’s stock valued at $112,000 after acquiring an additional 2,447 shares during the last quarter. Xponance LLC raised its stake in shares of LifeStance Health Group by 26.4% in the 4th quarter. Xponance LLC now owns 13,144 shares of the company’s stock valued at $93,000 after acquiring an additional 2,745 shares in the last quarter. Finally, State of Wyoming raised its stake in shares of LifeStance Health Group by 3.8% in the 3rd quarter. State of Wyoming now owns 89,927 shares of the company’s stock valued at $495,000 after acquiring an additional 3,298 shares in the last quarter. Institutional investors and hedge funds own 85.50% of the company’s stock.

Key Stories Impacting LifeStance Health Group

Here are the key news stories impacting LifeStance Health Group this week:

• Positive Sentiment: Board authorizes a $100 million share repurchase (up to ~3.6% of shares), signaling management thinks the stock is undervalued and reducing float. LifeStance to Repurchase $100M
• Positive Sentiment: Multiple firms raised price targets and ratings (UBS to $12, Canaccord to $10, KeyCorp to $9), increasing visible upside and buy-side interest. Analyst Price Target Raises
• Positive Sentiment: Company set 2026 revenue target of $1.615B–$1.655B and highlighted progress on AI and EHR initiatives that can drive scale and margin expansion over time. 2026 Revenue Target & Initiatives
• Neutral Sentiment: Coverage roundup: several analysts reviewed the stock following the quarter; the market reaction depends on whether upgrades translate into sustained buy-side flows. 6 Analysts Assess LFST
• Negative Sentiment: Q4 EPS missed expectations (reported ~$0.03 vs. ~$0.06 expected) despite revenue beating estimates; EPS weakness and still-modest margins remain near-term headwinds. Q4 2025 Earnings Highlights
• Negative Sentiment: Selling stockholders filed a secondary offering of 25M shares (company not raising proceeds), creating potential supply/overhang that can cap near-term upside. Secondary Public Offering

LifeStance Health Group Company Profile

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.